MuSK–antibody positive pure ocular myasthenia gravis

[1]  S. Zierz,et al.  Successful treatment of MuSK antibody–positive myasthenia gravis with rituximab , 2006, Muscle & nerve.

[2]  S. Batish,et al.  Anti-MuSK myasthenia gravis presenting with purely ocular findings. , 2005, Archives of neurology.

[3]  A. Vincent,et al.  Clinical comparison of muscle‐specific tyrosine kinase (MuSK) antibody‐positive and ‐negative myasthenic patients , 2004, Muscle & nerve.

[4]  A. Vincent,et al.  Detection and characterization of MuSK antibodies in seronegative myasthenia gravis , 2004, Annals of neurology.

[5]  J. Goldstein,et al.  The effect of prednisone on the progression from ocular to generalized myasthenia gravis , 2004, Journal of the Neurological Sciences.

[6]  J. King,et al.  Immunotherapy of Ocular Myasthenia Gravis Reduces Conversion to Generalized Myasthenia Gravis , 2003, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[7]  P. Tonali,et al.  Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. , 2003, Brain : a journal of neurology.

[8]  A. Vincent,et al.  Clinical aspects of MuSK antibody positive seronegative MG , 2003, Neurology.

[9]  A. Vincent,et al.  Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets , 2003, The Lancet Neurology.

[10]  M. Kupersmith,et al.  Development of generalized disease at 2 years in patients with ocular myasthenia gravis. , 2003, Archives of neurology.

[11]  R. Barohn,et al.  Myasthenia gravis: recommendations for clinical research standards1 , 2000 .

[12]  R. Barohn,et al.  Myasthenia gravis , 2000, Neurology.

[13]  R. Schwab,et al.  Myasthenia gravis , 1955, Neurology.